Quetiapine for mania due to traumatic brain injury

CNS Spectrums

Volumn 12, Issue 10, 2007, Pages 764-769

  Oster, Timothy J ^a,b   Anderson, C Alan ^b   Filley, Christopher M ^b   Wortzel, Hal S ^b   Arciniegas, David B ^a,b  

^a HealthONE Spalding Rehabilitation Hospital   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLONIDINE; FENTANYL; GABAPENTIN; HALOPERIDOL; LORAZEPAM; MORPHINE SULFATE; OPIATE; PHENYTOIN; PROMETHAZINE; QUETIAPINE;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BRAIN CONTUSION; CASE REPORT; CLINICAL FEATURE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FUNCTIONAL DISEASE; GLASGOW COMA SCALE; HUMAN; LIVER INJURY; MALE; MANIA; MONOTHERAPY; NEUROLOGIC EXAMINATION; PNEUMOTHORAX; PRIORITY JOURNAL; RIB FRACTURE; SEIZURE; SPLEEN INJURY; THERAPY EFFECT; TRAFFIC ACCIDENT; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 35948936864     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900015455     Document Type: Article

References (59)

1. Jorge RE, Robinson RG, Starkstein SE, Arndt SV, Forrester AW, Geisler FH. Secondary mania following traumatic brain injury. Am J Psychiatry. 1993;150:916-921.
2. van Reekum R, Cohen T, Wong J. Can traumatic brain injury cause psychiatric disorders? J Neuropsychiatry Clin Neurosci. 2000;12:316-327.
3. Jorge R, Robinson RG. Mood disorders following traumatic brain injury. Int Rev Psychiatry. 2003;15:317-327.
4. Warden DL, Gordon B, McAllister TW, et al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J Neurotrauma. 2006;23:1468-1501.
5. Starkstein SE, Pearlson GD, Boston J, Robinson RG. Mania after brain injury. A controlled study of causative factors. Arch Neurol. 1987;44:1069-1073.
6. Stewart JT, Hemsath RH. Bipolar illness following traumatic brain injury: treatment with lithium and carbamazepine. J Clin Psychiatry. 1988;49:74-75.
7. Bouvy PF, van de Wetering BJ, Meerwaldt JD, Bruijn JB. A case of organic brain syndrome following head injury sucessfully treated with carbamazepine. Acta Psychiatr Scand. 1988;77:361-363.
8. Kim E, Humaran TJ. Divalproex in the management of neuropsychiatric complications of remote acquired brain injury. J Neuropsychiatry Clin Neurosci. 2002;14:202-205.
9. Pope HG, McElroy SL, Satlin A, Hudson JI, Keck PE Jr, Kalish R. Head injury, bipolar disorder and response to valproate. Compr Psychiatry. 1988;29:34-38.
10. Monji A, Yoshida I, Koga H, Tashiro K, Tashiro N. Brain injury-induced rapid-cycling affective disorder successfully treated with valproate. Psychosomatics. 1999;40:448-449.
11. Yassa R, Cvejic J. Valproate in the treatment of posttraumatic bipolar disorder in a psychogeriatric patient. J Geriatr Psychiatry Neurol. 1994;7:55-57.
12. Mustafa B, Evrim O, Sari A. Secondary mania following traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2005;17:122-124.
13. Murai T, Fujimoto S. Rapid cycling bipolar disorder after left temporal polar damage. Brain Inj. 2003;17:355-358.
14. Arciniegas DB, Topkoff J, Silver JM. Neuropsychiatric aspects of traumatic brain injury. Curr Treat Options Neurol. 2000;2:169-186.
15. Arciniegas DB, Harris SN, Brousseau KM. Psychosis following traumatic brain injury. Int Rev Psychiatry. 2003;15:328-340.
16. Smith KR Jr, Goulding PM, Wilderman D, Goldfader PR, Holterman-Hommes P, Wei F. Neurobehavioral effects of phenytoin and carbamazepine in patients recovering from brain trauma: a comparative study. Arch Neurol. 1994;51:653-660.
17. Hornstein A, Seliger G. Cognitive side effects of lithium in closed head injury. J Neuropsychiatry Clin Neurosci. 1989;1:446-447.
18. Massagli TL. Neurobehavioral effects of phenytoin, carbamazepine, and valproic acid: implications for use in traumatic brain injury. Arch Phys Med Rehabil. 1991;72:219-226.
19. Glenn MB, Wroblewski B, Parziale J, Levine L, Whyte J, Rosenthal M. Lithium carbonate for aggressive behavior or affective instability in ten brain-injured patients. Am J Phys Med Rehabil. 1989:68:221-226.
20. Dikmen SS, Machamer JE, Winn HR, Anderson GD, Temkin NR. Neuropsychological effects of valproate in traumatic brain injury: a randomized trial. Neurology. 2000;54:895-902.
21. Temkin NR, Dikmen SS, Anderson GD, et al. Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg. 1999;91:593-600.
22. Wilson MS, Gibson CJ, Hamm RJ. Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats. Am J Phys Med Rehabil. 2003;82:871-879.
23. Rao N, Jellinek HM, Woolston DC. Agitation in closed head injury: Haloperidol effects on rehabilitation outcome. Arch Phys Med Rehabil. 1985;66:30-34.
24. Elovic EP, Lansang R, Li Y, Ricker JH. The use of atypical antipsychotics in traumatic brain injury. J Head Trauma Rehabil. 2003;18:177-195.
25. Stanislav SW. Cognitive effects of antipsychotic agents in persons with traumatic brain injury. Brain Inj. 1997;11:335-341.
26. Kline AE, Massucci JL, Zafonte RD, Dixon CE, Defeo JR, Rogers EH. Differential effects of single versus multiple administrations of haloperidol and risperidone on functional outcome after experimental brain trauma. Crit Care Med. 2007;35:919-924.
27. Bleiberg J, Garmoe W, Cederquist J. Dexedrine on performance consistency following brain injury: a double-blind placebo crossover case study. Neuropsychiatry Neuropsych Behav Neurol. 1993;6.245-248.
28. Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE Jr. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2006;67:509-516.
29. Krieger D, Hansen K, McDermott C, et al. Loxapine versus olanzapine in the treatment of delirium following traumatic brain injury. NeuroRehabilitation. 2003;18:205-208.
30. Temple MJ. Use of atypical antipsychotics in the management of post-traumatic confusional states in traumatic brain injury. J R Army Med Corps. 2003;149:54-55.
31. Bennouna M, Greene VB, Defranoux L. Adjuvant galantamine to risperidone improves negative and cognitive symptoms in a patient presenting with schizophrenialike psychosis after traumatic brain injury. J Clin Psychopharmacol. 2005;25:505-507.
32. Schreiber S, Klag E, Gross Y, Segman RH, Pick CG. Beneficial effect of risperidone on sleep disturbance and psychosis following traumatic brain injury. Int Clin Psychopharmacol. 1998;13:273-275.
33. Kim E, Bijlani M. A pilot study of quetiapine treatment of aggression due to traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2006;18:547-549.
34. Michals ML, Crismon ML, Roberts S, Childs A. Clozapine response and adverse effects in nine brain-injured patients. J Clin Psychopharmacol. 1993;13:198-203.
35. Cole P, Rabasseda X. Quetiapine in bipolar disorder: increasing evidence of efficacy and tolerability. Drugs Today (Barc). 2004;40:837-852.
36. Serretti A, De RD, Lorenzi C, Berardi D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem. 2004;11:343-358.
37. Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry. 2002;14:123-129.
38. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159:1018-1028.
39. Harvey PD. Cognitive and functional effects of atypical antipsychotic medications. J Clin Psychiatry. 2006;67:e13.
40. Harvey PD, Bowie CR, Loebel A. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine. J Neuropsychiatry Clin Neurosci. 2006;18:54-63.
41. Macqueen G, Young T. Cognitive effects of atypical antipsychotics: focus on bipolar spectrum disorders. Bipolar Disord. 2003;5:53-61.
42. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
43. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55:1621-1626.
44. Guide for the Uniform Data Set for Medical Rehabilitation (Including the FIMTM instrument). Version 5.1. Buffalo, NY: State University of New York at Buffalo; 1997.
45. Shukla S, Cook BL, Mukherjee S, Godwin C, Miller MG. Mania following head trauma. Am J Psychiatry. 1987;144:93-96.
46. Starkstein SE, Boston JD, Robinson RG. Mechanisms of mania after brain injury. 12 case reports and review of the literature. J Nerv Ment Dis. 1988;176:87-100.
47. Starkstein SE, Mayberg HS, Berthier ML, et al. Mania after brain injury: neuroradiological and metabolic findings. Ann Neurol. 1990;27:652-659.
48. Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord. 2005;7(suppl):21-33.
49. Newman-Tancredi A, Gavaudan S, Conte C, et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998;355:245-256.
50. Bymaster FP, Falcone JF, Bauzon D, et al. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol. 2001;430:341-349.
51. Tyson PJ, Roberts KH, Mortimer AM. Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci. 2004;114:593-611.
52. Yatham LN, Goldstein JM, Vieta E, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66(suppl):40-48.
53. Buhot MC, Martin S, Segu L. Role of serotonin in memory impairment. Ann Med. 2000;32:210-221.
54. Ichikawa J, Li Z, Dai J, Meltzer HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 2002;956:349-357.
55. Velligan DI, Prihoda TJ, Sui D, Ritch JL, Maples N, Miller AL. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry. 2003;84:524-531.
56. Randolph C. RBANS Manual: Repeatable Battery for the Assessment of Neuropsychological Status. San Antonio, Tex: The Psychological Corporation (Harcourt); 1998.
57. Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology. 2003;28:1491-1500.
58. Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord. 2006;98:247-252.
59. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943.